We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Amarantus

News List

Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries firstwordpharma
January 13, 2019
IDEA, who have supported 8 of the 15 biggest biopharmaceutical launches in the past 3 years, will partner with Amarantus in a novel royalty-split model.
Amarantus reacquires three diagnostic tests biospectrumasia
April 10, 2018
Under the terms of the deal, Amarantus will cancel about $722,000 in liabilities, owed by Avant. Amarantus will issue to Avant 1 million shares of its common stock, and Avant will issue to Amarantus an additional 32 million shares of its common stock as a
Amarantus forms Elto Pharma for CNS Disorders and MANF Therapeutics for Ophthalmology europeanpharmaceuticalreview
April 19, 2017
Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine...
Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focu americanpharmaceuticalreview
April 18, 2017
Amarantus Bioscience Holdings, Inc. has announced it has formed a wholly-owned subsidiary named Elto Pharma, Inc. for the purpose of further development of Eltoprazine...